These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25927855

  • 1. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.
    Mol Cancer; 2015 May 01; 14():99. PubMed ID: 25927855
    [Abstract] [Full Text] [Related]

  • 2. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV, Allen JE, Dicker DT, El-Deiry WS.
    Cancer Res; 2015 Apr 01; 75(7):1423-32. PubMed ID: 25712124
    [Abstract] [Full Text] [Related]

  • 3. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
    Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS.
    Sci Transl Med; 2013 Feb 06; 5(171):171ra17. PubMed ID: 23390247
    [Abstract] [Full Text] [Related]

  • 4. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK, Allen JE, Dicker DT, El-Deiry WS.
    Cell Cycle; 2015 Aug 03; 14(15):2422-8. PubMed ID: 26030065
    [Abstract] [Full Text] [Related]

  • 5. Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.
    Cheng L, Liu YY, Lu PH, Peng Y, Yuan Q, Gu XS, Jin Y, Chen MB, Bai XM.
    Oncotarget; 2017 Apr 25; 8(17):28385-28394. PubMed ID: 28415690
    [Abstract] [Full Text] [Related]

  • 6. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.
    Zhang Q, Wang H, Ran L, Zhang Z, Jiang R.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):260-266. PubMed ID: 27233611
    [Abstract] [Full Text] [Related]

  • 7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS.
    Neoplasia; 2020 Dec 05; 22(12):725-744. PubMed ID: 33142238
    [Abstract] [Full Text] [Related]

  • 8. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS.
    Neoplasia; 2021 Aug 05; 23(8):792-810. PubMed ID: 34246076
    [Abstract] [Full Text] [Related]

  • 9. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
    Feng Y, Zhou J, Li Z, Jiang Y, Zhou Y.
    PLoS One; 2016 Aug 05; 11(9):e0162133. PubMed ID: 27626799
    [Abstract] [Full Text] [Related]

  • 10. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.
    Oncotarget; 2016 Nov 08; 7(45):74380-74392. PubMed ID: 27602582
    [Abstract] [Full Text] [Related]

  • 11. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
    Allen JE, Crowder RN, El-Deiry WS.
    PLoS One; 2015 Nov 08; 10(11):e0143082. PubMed ID: 26580220
    [Abstract] [Full Text] [Related]

  • 12. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo.
    Ray JE, Ralff MD, Jhaveri A, Zhou L, Dicker DT, Ross EA, El-Deiry WS.
    Cancer Biol Ther; 2021 Dec 02; 22(10-12):554-563. PubMed ID: 34696710
    [Abstract] [Full Text] [Related]

  • 13. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, Carneiro BA, Safran H, Prabhu VV, Ross EA, Lee S, El-Deiry WS.
    Cancer Biol Ther; 2021 Dec 02; 22(10-12):607-618. PubMed ID: 34856854
    [Abstract] [Full Text] [Related]

  • 14. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
    Zhao R, Li Y, Gorantla S, Poluektova LY, Lin H, Gao F, Wang H, Zhao J, Zheng JC, Huang Y.
    Antiviral Res; 2019 Aug 02; 168():134-145. PubMed ID: 31158413
    [Abstract] [Full Text] [Related]

  • 15. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
    Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS.
    Cancer Res; 2015 Apr 15; 75(8):1668-74. PubMed ID: 25681273
    [Abstract] [Full Text] [Related]

  • 16. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS.
    Neoplasia; 2018 Jan 15; 20(1):80-91. PubMed ID: 29216597
    [Abstract] [Full Text] [Related]

  • 17. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW.
    Cell Death Differ; 2016 Nov 01; 23(11):1886-1896. PubMed ID: 27612013
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.
    Cell Cycle; 2017 Oct 02; 16(19):1790-1799. PubMed ID: 28489985
    [Abstract] [Full Text] [Related]

  • 19. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS, Zhou L, Prabhu VV, Lee S, Miner TJ, Ross EA, El-Deiry WS.
    Am J Cancer Res; 2023 Oct 02; 13(12):6290-6312. PubMed ID: 38187068
    [Abstract] [Full Text] [Related]

  • 20. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
    Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS.
    Mol Cancer Ther; 2017 Jul 02; 16(7):1290-1298. PubMed ID: 28424227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.